FDA rejects oral Type I diabetes drug
The FDA has dashed Sanofi’s hopes of launching its type I diabetes drug, Zynquista, this year.
Read More
Tag: Type I diabetes
Study shows reduced hypoglycaemia after switch to Tresiba
Novo Nordisk’s Tresiba has been found to be efficient in treating diabetes compared to other basal insulins.
Read More
Novo Nordisk seeks label update for Fiasp in children
Novo Nordisk has submitted applications to both US and EU regulators for use of its fast-acting insulin Fiasp in children.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
